智通财经APP获悉，周二，葛兰素史克(GSK.US)涨逾4%，报42.94美元。消息面上，9月29日，葛兰素 史克公司宣布卢克·米尔斯(Luke Miels)已获任命为首席执行官候选人，并将于2026年1月1日正式担任首 席执行官一职，接替现任首席执行官艾玛·沃尔姆斯利(Emma Walmsley)。米尔斯于 2017 年加入葛兰素 史克公司，目前担任首席商业官，他在构建葛兰素史克的专科药物产品组合(尤其是肿瘤学和呼吸系统 领域)方面发挥了关键作用。在加入葛兰素史克之前，米尔斯曾在阿斯利康、罗氏和赛诺菲等公司担任 过多个高级职务。 （原标题：美股异动 | 葛兰素史克(GSK.US)涨逾4% 高盛：换帅或推动投资者重新估值） 高盛认为，新任首席执行官的首要沟通内容将是向市场保证葛兰素史克实现其长期目标的策略，尤其是 其到 2031 年实现超过 400 亿英镑销售额的销售指引，这也是新闻稿中所重申的内容。此外，高盛预计 投资者将会关注新首席执行官如何能够提升公司创新能力的相关细节。高盛认为，这对于推动该股票实 现有意义的重新估值至关重要，因为该股票一直处于同行业股票的较低水平。 ...

Core Viewpoint - GlaxoSmithKline (GSK) shares rose over 4% to $42.94 following the announcement of Luke Miels as the CEO candidate, set to officially take over on January 1, 2026, from current CEO Emma Walmsley [1] Group 1: Leadership Transition - Luke Miels has been appointed as the CEO candidate and will succeed Emma Walmsley in 2026 [1] - Miels joined GSK in 2017 and currently serves as Chief Commercial Officer, playing a key role in developing GSK's specialty pharmaceuticals portfolio, particularly in oncology and respiratory fields [1] - Prior to GSK, Miels held senior positions at AstraZeneca, Roche, and Sanofi [1] Group 2: Market Expectations - Goldman Sachs believes the new CEO's primary communication will focus on assuring the market of GSK's strategy to achieve its long-term goals, particularly the sales guidance of over £40 billion by 2031, which was reiterated in the press release [1] - Investors are expected to pay close attention to how the new CEO can enhance the company's innovation capabilities, which is deemed crucial for driving a meaningful revaluation of the stock [1] - GSK's stock has been trading at lower levels compared to its industry peers, making the focus on innovation particularly significant [1]